Michael S. Lawrence

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Supplementary Figure S11 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Figure S11 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Figure S23 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Figure S3 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Table S4 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Figure S19 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Figure 5 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Figure S16 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Figure S24 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Figure S17 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Figure S21 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Figure S3 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Figure S5 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Figure S8 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Figure S15 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary References 1 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Figure 2 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Table S4 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Figure S13 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18

• Supplementary Figure S4 from Circulating Tumor Cells Predict Response to the DLL3-Targeting Bispecific Antibody Tarlatamab

  2026-06-18